Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04102098 · ClinicalTrials.gov registry record · Phase 3
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
A Phase 3 study of Carcinoma, Hepatocellular, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 668
- Enrollment target
- 20
- Study locations
NCT04102098: Active Phase 3 study of Carcinoma, Hepatocellular, sponsored by Hoffmann-La Roche.
NCT04102098 is a Phase 3 study of Carcinoma, Hepatocellular that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 668 participants, above the 588-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (14% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04102098, a Phase 3 study of Carcinoma, Hepatocellular, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 668 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for disease recurrence.
Primary Outcome
RFS is defined as the time from randomization to the first documented occurrence of intrahepatic or extrahepatic HCC as determined by an IRF, or death from any cause (whichever occurs first).
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
Study Locations (20)
Other
- Lkh-Univ. Klinikum Graz - Graz
- Klinikum Klagenfurt am Wörtersee - Klagenfurt
- Medizinische Universität Wien - Vienna
- Imeldaziekenhuis - Bonheiden
- AZ Delta (Campus Rumbeke) - Roeselare
Texas
- The University of Texas Southwestern Medical Center at Dallas - Dallas
- MD Anderson Cancer Center - Houston
California
- Kaiser Permanente Los Angeles - Los Angeles
Maryland
- Mercy Medical Center - Baltimore
Michigan
- Henry Ford Health System - Detroit
New York
- Columbia University Medical Center - New York
Pennsylvania
- Thomas Jefferson University - Philadelphia
Washington
- Swedish Cancer Inst. - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 668 participants |
| Start Date | 2019-12-31 |
| Est. Completion | 2026-05-15 |
| Phase | Phase 3 |
What the registry record for NCT04102098 still lists
NCT04102098 is an interventional study that assigns participants to a tested intervention. The registered 668 participants enrollment target is mid-sized for trials with a published cap, above the 588-participant average among 27 other Carcinoma, Hepatocellular trials with a reported enrollment target (14% higher).
The record links to 1 condition, with Carcinoma, Hepatocellular appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT04102098 names 20 study sites across 15 states, led by Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT04102098 about?
NCT04102098 is a clinical study titled "A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation". This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for disease recurrence.
What is the current status of trial NCT04102098?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 668 participants. The study started on 2019-12-31. Estimated completion is 2026-05-15.
What conditions does trial NCT04102098 study?
This clinical trial studies the following conditions: Carcinoma, Hepatocellular.
What interventions are being tested in trial NCT04102098?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT04102098?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04102098 being conducted?
This trial has 20 study locations across California, Maryland, Michigan, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Hepatocellular
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04102098's enrollment target sits among peer trials
668 6th of 27 higher than 22 of 27 other Carcinoma, Hepatocellular trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Hepatocellular trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
COMPLETED · Phase 3
-
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
COMPLETED · Phase 3
-
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
COMPLETED · Phase 3
-
A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
COMPLETED · Phase 3
-
90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04155034 · 668 participants · Phase 3
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
- NCT04179981 · 668 participants · NA
Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)
- NCT05006482 · 668 participants · Phase 3
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
- NCT02984761 · 670 participants · NA
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI